GLADSTONE AIREWELE

Concepts (208)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Anemia, Sickle Cell
19
2024
334
2.990
Why?
Hydroxyurea
2
2020
81
0.760
Why?
Recombinases
2
2024
24
0.420
Why?
Glioma
4
2007
491
0.410
Why?
Hematologic Diseases
2
2025
78
0.380
Why?
Erythrocyte Aging
1
2011
8
0.380
Why?
Antisickling Agents
1
2011
17
0.370
Why?
Anemia, Iron-Deficiency
2
2024
132
0.370
Why?
Hemolysis
1
2011
105
0.360
Why?
Acetamides
1
2011
49
0.360
Why?
Cytapheresis
1
2009
1
0.350
Why?
Vasodilator Agents
2
2015
203
0.310
Why?
Erythrocyte Transfusion
1
2009
121
0.310
Why?
Anemia
2
2022
339
0.290
Why?
Neoplasm Regression, Spontaneous
1
2007
8
0.290
Why?
Capacity Building
2
2025
25
0.280
Why?
Brain Stem Neoplasms
1
2007
39
0.280
Why?
Nucleic Acid Amplification Techniques
2
2024
65
0.280
Why?
Child
25
2025
24208
0.280
Why?
Cerebral Infarction
3
2014
43
0.260
Why?
Child, Preschool
17
2024
13862
0.260
Why?
Pain
4
2017
470
0.240
Why?
Hemoglobin, Sickle
4
2021
21
0.240
Why?
Neonatal Screening
2
2017
184
0.230
Why?
Blood Transfusion
3
2021
302
0.220
Why?
Magnesium Sulfate
1
2014
51
0.220
Why?
Randomized Controlled Trials as Topic
3
2023
1070
0.220
Why?
Menorrhagia
1
2024
74
0.220
Why?
Magnetic Resonance Imaging
3
2011
3518
0.220
Why?
Adolescent
18
2024
19087
0.210
Why?
Arterial Occlusive Diseases
1
2014
127
0.210
Why?
Interdisciplinary Communication
1
2014
134
0.210
Why?
Thrombocytosis
1
2022
34
0.200
Why?
Emergency Service, Hospital
3
2024
1069
0.200
Why?
Alleles
2
2024
1607
0.200
Why?
Angola
2
2018
5
0.190
Why?
Venous Thromboembolism
1
2024
162
0.190
Why?
Analgesics, Opioid
2
2023
401
0.180
Why?
Acquired Immunodeficiency Syndrome
1
2022
230
0.180
Why?
Humans
35
2025
123180
0.180
Why?
HIV Infections
2
2022
1868
0.180
Why?
Malaria
1
2021
82
0.180
Why?
Thrombocytopenia
1
2022
229
0.180
Why?
Iron
1
2022
261
0.170
Why?
Neurofibromatosis 1
1
2001
59
0.170
Why?
Maximum Tolerated Dose
1
2020
157
0.170
Why?
Malnutrition
1
2022
196
0.170
Why?
Incidental Findings
1
2010
124
0.160
Why?
Pediatrics
2
2018
1139
0.160
Why?
Hematology
1
2018
37
0.150
Why?
Hemoglobins
2
2022
300
0.150
Why?
Blood Pressure
2
2014
1314
0.150
Why?
Female
19
2024
65428
0.150
Why?
Male
18
2024
60022
0.140
Why?
Paper
1
2017
6
0.140
Why?
Algorithms
1
2024
1597
0.140
Why?
Brain Diseases
1
2010
294
0.140
Why?
Quality Improvement
3
2024
624
0.140
Why?
Platelet Count
2
2022
133
0.130
Why?
Infant
9
2024
12323
0.130
Why?
Ikaros Transcription Factor
1
2015
28
0.130
Why?
Academic Medical Centers
1
2017
298
0.130
Why?
Hematologic Neoplasms
1
2018
286
0.120
Why?
Patient Care
2
2018
100
0.120
Why?
Magnesium
1
2015
120
0.120
Why?
Stroke
1
2023
958
0.120
Why?
Prognosis
4
2024
4508
0.120
Why?
Quality of Life
3
2017
1932
0.120
Why?
Length of Stay
3
2015
1284
0.120
Why?
Retrospective Studies
8
2024
15981
0.110
Why?
Body Height
1
2014
210
0.110
Why?
Neoplasms
2
2014
2766
0.110
Why?
Lamivudine
2
2022
25
0.100
Why?
Severity of Illness Index
2
2018
2838
0.100
Why?
Infant, Newborn
6
2021
8089
0.100
Why?
Global Health
1
2017
557
0.100
Why?
Young Adult
6
2023
8870
0.100
Why?
Africa South of the Sahara
2
2025
121
0.100
Why?
beta-Thalassemia
1
2011
28
0.100
Why?
Risk Factors
6
2024
10000
0.100
Why?
Intermediate-Conductance Calcium-Activated Potassium Channels
1
2011
14
0.090
Why?
Double-Blind Method
2
2015
1588
0.090
Why?
Acute Chest Syndrome
1
2011
9
0.090
Why?
Bone Marrow Transplantation
1
2014
576
0.090
Why?
Follow-Up Studies
4
2015
5048
0.090
Why?
Practice Guidelines as Topic
2
2024
1259
0.090
Why?
Tumor Suppressor Protein p53
1
2015
715
0.090
Why?
Hematocrit
1
2011
110
0.090
Why?
Body Weight
1
2014
999
0.090
Why?
Drug Administration Schedule
1
2011
730
0.080
Why?
Multicenter Studies as Topic
2
2023
264
0.080
Why?
Infusions, Intravenous
2
2015
533
0.080
Why?
Chest Pain
1
2009
126
0.080
Why?
Brain
1
2010
2947
0.080
Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
2015
804
0.080
Why?
Tuberculosis
1
2014
573
0.070
Why?
Respiratory Insufficiency
1
2009
234
0.070
Why?
Hospital Mortality
2
2023
1004
0.070
Why?
Respiration, Artificial
1
2009
455
0.070
Why?
Syndrome
1
2009
1114
0.070
Why?
Neurologic Examination
1
2007
192
0.070
Why?
Internship and Residency
1
2017
1158
0.070
Why?
Brain Neoplasms
2
2007
1217
0.070
Why?
Adult
6
2024
29039
0.060
Why?
Case-Control Studies
2
2022
3260
0.060
Why?
beta-Globins
1
2024
6
0.060
Why?
Leukemia, Myeloid, Acute
1
2010
532
0.060
Why?
Hospitals, Special
1
2014
14
0.060
Why?
Narcotics
1
2014
63
0.060
Why?
Glutathione Transferase
1
2004
153
0.050
Why?
Isoenzymes
1
2004
223
0.050
Why?
Clinical Trials, Phase III as Topic
1
2023
68
0.050
Why?
Point Mutation
1
2024
348
0.050
Why?
Nevirapine
1
2022
15
0.050
Why?
Academies and Institutes
1
2023
83
0.050
Why?
Cooperative Behavior
1
2014
219
0.050
Why?
Interprofessional Relations
1
2014
144
0.050
Why?
Hypotension
1
2014
175
0.050
Why?
CD4 Lymphocyte Count
1
2022
229
0.050
Why?
Middle Aged
5
2015
25980
0.050
Why?
Arginine
1
2023
298
0.050
Why?
Anti-Inflammatory Agents
1
2014
280
0.050
Why?
Optic Nerve Glioma
1
2001
21
0.050
Why?
Informed Consent
1
2014
342
0.050
Why?
Polymorphism, Genetic
1
2004
810
0.050
Why?
Disease Management
1
2024
516
0.040
Why?
United States
3
2023
10618
0.040
Why?
Aged
3
2011
19072
0.040
Why?
Malawi
1
2021
389
0.040
Why?
Confidence Intervals
1
2010
280
0.040
Why?
Probability
1
2010
322
0.040
Why?
Reference Values
1
2001
696
0.040
Why?
Intensive Care Units, Pediatric
1
2023
470
0.040
Why?
Pilot Projects
2
2015
1387
0.040
Why?
Hospitals, Pediatric
1
2014
780
0.040
Why?
Point-of-Care Systems
1
2021
172
0.040
Why?
Death Certificates
1
1998
9
0.040
Why?
Cytokines
1
2014
1283
0.040
Why?
Isoelectric Focusing
1
2017
24
0.040
Why?
Saponins
1
2017
22
0.040
Why?
Sulfites
1
2017
30
0.040
Why?
Canada
1
1998
294
0.040
Why?
Treatment Outcome
2
2011
12103
0.040
Why?
Limit of Detection
1
2017
59
0.040
Why?
Solubility
1
2017
131
0.040
Why?
Texas
2
2007
3548
0.030
Why?
Sex Factors
1
2001
1257
0.030
Why?
Patient Selection
1
2010
685
0.030
Why?
Sensitivity and Specificity
1
2021
2024
0.030
Why?
Hospitalization
1
2024
1733
0.030
Why?
Fellowships and Scholarships
1
2018
272
0.030
Why?
Health Status
1
2017
374
0.030
Why?
Karyotyping
1
2015
329
0.030
Why?
Morbidity
1
2015
240
0.030
Why?
Biomarkers
1
2014
2943
0.030
Why?
Intention to Treat Analysis
1
2014
56
0.030
Why?
Transfusion Reaction
1
2014
38
0.030
Why?
Infant Mortality
1
2015
175
0.030
Why?
Mass Screening
1
2010
790
0.030
Why?
Ferritins
1
2014
96
0.030
Why?
Anthropometry
1
2014
197
0.030
Why?
Intelligence
1
2014
98
0.030
Why?
Education, Medical, Graduate
1
2018
510
0.030
Why?
Single-Blind Method
1
2014
235
0.030
Why?
In Situ Hybridization, Fluorescence
1
2015
757
0.030
Why?
Prevalence
1
2010
2405
0.030
Why?
Allografts
1
2014
190
0.030
Why?
Incidence
1
2001
3050
0.030
Why?
Sequence Deletion
1
2015
527
0.030
Why?
Cost-Benefit Analysis
1
2015
499
0.030
Why?
Secondary Prevention
1
2014
211
0.030
Why?
Oligonucleotide Array Sequence Analysis
1
2015
1013
0.020
Why?
Asymptomatic Diseases
1
2011
77
0.020
Why?
Reproducibility of Results
1
1998
2851
0.020
Why?
Risk Assessment
1
2010
3332
0.020
Why?
Sex Distribution
1
2011
294
0.020
Why?
Daunorubicin
1
2010
27
0.020
Why?
Aminoglycosides
1
2010
45
0.020
Why?
Cytogenetic Analysis
1
2010
79
0.020
Why?
Cytarabine
1
2010
98
0.020
Why?
Etoposide
1
2010
117
0.020
Why?
Neoplasm, Residual
1
2010
121
0.020
Why?
Remission Induction
1
2010
300
0.020
Why?
Disease-Free Survival
1
2010
861
0.020
Why?
Multivariate Analysis
1
2011
1418
0.020
Why?
Flow Cytometry
1
2010
803
0.020
Why?
Family Health
1
2007
259
0.020
Why?
SEER Program
1
2007
193
0.020
Why?
Cluster Analysis
1
2007
401
0.020
Why?
Prospective Studies
1
2017
6028
0.020
Why?
Antibodies, Monoclonal, Humanized
1
2010
502
0.020
Why?
Survival Rate
1
2010
1995
0.020
Why?
Oligodendroglioma
1
2004
24
0.010
Why?
Glutathione S-Transferase pi
1
2004
25
0.010
Why?
Antibodies, Monoclonal
1
2010
1015
0.010
Why?
Polymorphism, Restriction Fragment Length
1
2004
143
0.010
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2010
1229
0.010
Why?
Astrocytoma
1
2004
102
0.010
Why?
Cross-Sectional Studies
1
2011
3377
0.010
Why?
Ependymoma
1
2004
133
0.010
Why?
Mutation
1
2015
5774
0.010
Why?
Neoplasm Metastasis
1
2004
649
0.010
Why?
Proportional Hazards Models
1
2004
1306
0.010
Why?
Polymerase Chain Reaction
1
2004
1586
0.010
Why?
Logistic Models
1
2004
1799
0.010
Why?
Genotype
1
2004
2548
0.010
Why?
Genetic Predisposition to Disease
1
2007
3098
0.010
Why?
Time Factors
1
2004
6201
0.010
Why?
AIREWELE's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (208)
Explore
_
Co-Authors (47)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_